Jun. 4 at 12:10 AM
$CNTB started a small position here. I usually don’t buy pre approval bios but this one seems different with China data validations. COPD is a big market (of course right now we are only in emergency setting). I was in Verona which had first approved COPD drug and was bought for 10 billion last summer.
Aside from potential Phase 2 data surprise and dilution (not if they get China approval and milestone of over 100 mil), any other potential bear thesis? Is “china” relationahip a political concern here?
Anyone know much about Eli Lilly’s stake in the company?
I am also happy to see perceptive with a tiny stake. It, along with Avorro, is the most successful bio funds IMO.
